Thoracic surgeon David Jones and medical oncologist Charles Rudin, internationally recognized leaders in their fields, to head the Thoracic Surgical Service and the Thoracic Oncology Service, respectively.
A Memorial Sloan-Kettering study shows that an abnormal cell pattern found in the tumor tissue of some lung cancer patients may help to predict which tumors are more likely to recur after surgery.
Dr. Rizk discusses how the team of experts expedites treatment for patients, and uses minimally invasive techniques to diagnose and treat thoracic cancers when possible.
A new guideline has established standards for testing lung cancer tumors for genetic abnormalities, giving more patients a chance to benefit from targeted therapies.
A team from Memorial Sloan-Kettering has found that the makeup of immune cells in a lung tumor and in tissue surrounding a tumor can predict whether the cancer will recur after surgery.
Dr. Huang discusses how minimally invasive, video-assisted, and robotic surgical techniques improve the treatment of patients with lung, esophageal, and thyroid cancers.
With the genomics revolution, scientists and physicians have increasingly been able to peer at the inner workings of tumor cells and pinpoint the specific genetic changes that transform them from their cells of origin into cancer.
Memorial Sloan-Kettering researchers have discovered a way that cancer cells may be able to exchange information by establishing long bridges between cells called tunneling nanotubes.
Dr. Finley, Co-Director of the Complex Airway Program, explains how he lays out a treatment plan with his patients, and determines which type of surgery fits best in the context of their lifestyle.
Thoracic surgeon Inderpal Sarkaria discusses the expertise of Memorial Sloan-Kettering surgeons at performing complex operations to treat cancers of the lung, esophagus, and chest wall.
In an interview, Dr. Bach talks about research showing that CT screening may prevent one in five cancer deaths for people at a very high risk of developing lung cancer.
Memorial Sloan-Kettering was one of the first centers to use this type of genetic testing for lung cancer patients and is currently one of the only centers testing for mutations in squamous cell carcinomas of the lung.
Congratulations to Mark Kris, Chief of the Thoracic Oncology Service, and Ann Culkin, nurse on the Thoracic Oncology Service, for receiving the Wholeness of Life Award 2011 from the HealthCare Chaplaincy.
Chief of Thoracic Oncology Mark Kris offers his perspective on a promising new tactic for treating lung and other cancers in this story from CBS Evening News with Scott Pelley. The strategy tailors cancer treatment to each individual patient.
In an extraordinary demonstration of excellence, five Memorial Sloan-Kettering physician-scientists were selected to participate in the press program at the 2011 American Society of Clinical Oncology annual meeting, held June 3-7 in Chicago.
Many people undergoing cancer treatment receive some form of radiation therapy to shrink and kill a tumor. A relatively new type of radiation therapy — called image-guided radiation therapy (IGRT) — utilizes high-tech imaging with extremely precise radiation beams, ensuring that radiation targets the tumor, sparing nearby healthy tissue. IGRT can be used to treat many types of cancer, including those that develop in the spine, lung, prostate, brain, bladder, esophagus, liver, and bone.
At Memorial Sloan-Kettering, as the genetics revolution continues to flourish, discoveries made in the laboratory are increasingly producing real-world benefits for cancer patients.
A study led by thoracic surgeon Prasad Adusumilli found that an abnormal cell pattern identified in the tumor tissue of some lung cancer patients may help to predict which tumors are more likely to recur after surgery.
Epidemiologist Peter Bach commented on draft recommendations from the US Preventive Services Task Force on screening for lung cancer, and Memorial Sloan-Kettering’s lung cancer screening decision tool was highlighted.
Thoracic oncologist Mark Kris, MD, was interviewed about the FDA approval of crizotinib (Xalkori®), a drug that shrinks tumors in lung-cancer patients with a rare genetic abnormality.
A new study detected one of ten such mutations in 54 percent of the 516 lung cancer patients tested at diagnosis. The results enabled doctors to select the most appropriate drug designed to block the identified mutation and choose other treatment options for those patients whose tumors did not have a mutation.
A new study by researchers at Memorial Sloan-Kettering Cancer Center reveals the genetic underpinnings of what causes lung cancer to quickly metastasize, or spread, to the brain and the bone - the two most prominent sites of lung cancer relapse.
A new, international study found that the combination of two drugs delays disease progression for patients with advanced non-small cell lung cancer (NSCLC).
A new study that shows lung cancer risk varies widely among smokers may help individuals and their doctors decide if voluntary screening is appropriate for them.